|
|
| Source: Yahoo Finance 08-24-2023 06:00:34 |  Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum as the company’s chief technology officer.
Read All |
| | | | | | | | |
|
